Ultimovacs ASA ULTMF:Over The Counter Mkt

*Data is delayed | Exchange | USD
Last | undefined
0.00UNCH (UNCH)
52 week range
0.00 - 0.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.00
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-

Key Stats

  • Market Cap22.4M
  • Shares Out34.41M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.00
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-
  • Market Cap22.4M
  • Shares Out34.41M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.55
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ultimovacs ASA

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacs’ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer...
Jonas Einarsson M.D.
Chairman of the Board
Carlos Sousa
Chief Executive Officer
Hans Eid
Chief Financial Officer
Audun Tornes
Chief Technology Officer
Address
Ullernchausseen 64
Oslo
0379
Norway